PPT-ART Resistance and Second Line Regimens

Learning Objectives Understand when to switch to a secondline regimen Know preferred secondline regimens for adults including pregnant and breastfeeding women adolescents and children Describe common drug resistance mutations and how they influence choosing a secondline regimen. Physics 2415 Lecture 11. Michael Fowler, . UVa. Today’s Topics. First we’ll mention capacitors. Power usage: kWh, etc.. The microscopic picture. Temperature dependence of resistivity. Drift speed and electron speed. Vincent Marconi, . MD. Outline. Transmitted Drug Resistance. Acquired Drug Resistance. Transmitted Drug Resistance. Europe. North America. Japan. Australia. Europe. 23K . pts. from 75 studies in 20 countries. Danielle Goodrich, MSIV. University of Maryland School of Medicine . Overview. Colorectal Cancer. Bowel Preparation Regimens. Survey. 2. Colorectal Cancer . Third most common cancer. Second leading cause of cancer-related deaths. James . Nuttall. Paediatric. Infectious Diseases Unit, . Red Cross War Memorial Children’s Hospital & University of Cape Town. Right to Care 6. th. Conference on Emerging Problems in . Paediatric. Rates of VTE* in Newly Diagnosed MM . Treatment. No Prophylaxis. Any Prophylaxis. ASA. Warfarin. 1-1.25 mg/d. Prophylactic LMWH. Therapeutic Anticoagulation. T alone . (95% CI) . 1.3 . (0.4–2.7) . Susan M. Graham . Assistant Professor, Medicine and Global Health. Adjunct Assistant Professor, Epidemiology. Presentation prepared by: . Susan M. Graham. Last Updated: . October 29, 2014. Susan M. Graham, MD MPH PhD. Manu Awasthi⁺. , . Manjunath. . Shevgoor. ⁺, Kshitij Sudan⁺, Rajeev Balasubramonian⁺, . Bipin. . Rajendran. ‡. , . Viji. . Srinivasan. ‡. ⁺. University of Utah, . ‡. IBM Research. Quick Summary. Bertrand Coiffier. Service d. ’. Hématologie. Hospices Civils de Lyon. Equipe . « Pathologie des Cellules Lymphoïdes ». UMR 5239 CNRS – UCB – ENS - HCL. The Lymphoma. Study Association. One question, lot of possibilities. introduction . of . DTG. Nandita Sugandhi. ICAP at Columbia University. No conflicts of interest to declare. Overview. Introducing . DTG in guidelines now. Programmatic Context. Eligible patient populations. Define drug resistance. Identify . factors that influence drug resistance. .. Identify . strategies for minimizing development of drug resistance.. Identify strategies for responding to detection of moderate to high levels of drug resistant HIV.. Dolutegravir based regimens in first- ad second-line HIV Treatment. Meg . Doherty,. MD, PhD, MPH. WHO Geneva. Sunday 21 July, 2019. Increase in people receiving ART over time . (62% ART coverage). Source: UNAIDS/WHO . Anastasiya Nestsiarovich, MD, PhD. Postdoctoral Fellow. University of New . Mexico Health Sciences Center. Department of Internal . Medicine. Center . for Global . Health. September 16, 2019. Research team:. ≥14kg). Ellen White. and Cissy Kityo. on behalf of the ODYSSEY trial team. CHIVA Conference, 3. rd. September 2021. . . . 15. TH . Annual Conference. Baseline characteristics. Constance A. Benson, MD. Professor of Medicine and Global Public Health. University of California San Diego. La Jolla, California. Goals for the Workshop. To describe the potential benefits of long-acting antiretroviral drugs (ARVs) for treatment and prevention of HIV infection.